India-Russia Pharma Ties Gather Pace as Moscow Offers Incentives for Local Manufacturing & API Expansion

Russian authorities have emphasized the importance of localizing production, particularly in high-demand therapeutic areas and biopharmaceuticals, while India has expressed interest in supplying critical medicines and setting up production units.

India-Russia pharma ties have advanced further following high-level discussions in Moscow, where both sides explored opportunities for market entry, local manufacturing, and collaboration among pharmaceutical industries and active pharmaceutical ingredient (API) manufacturers.

The engagement builds on ongoing efforts between the two countries to deepen healthcare and pharmaceutical cooperation, particularly after their 2024 agreement on joint drug development.

With global supply chains shifting and countries prioritizing self-reliance in medicines, Russia has been actively seeking partnerships to boost domestic production, while India continues to position itself as a major global supplier of affordable drugs and APIs.

The Moscow meeting has brought together representatives from over 60 Indian pharmaceutical companies, alongside Russian industry stakeholders and regulators. The discussions have focused on practical incentives for Indian firms entering Russia, including preferential investment loans, access to special economic zones, and participation in offset contracts that can secure up to a decade of guaranteed sales for locally manufactured products.

Russian authorities have emphasized the importance of localizing production, particularly in high-demand therapeutic areas and biopharmaceuticals. The country’s established scientific infrastructure, research hubs, and manufacturing capabilities are being positioned as enablers for joint innovation and technology transfer.

Indian companies, including API manufacturers, have expressed interest in addressing Russia’s import substitution needs by supplying critical medicines and setting up production units within the country. This aligns with Russia’s strategy to reduce dependency on external suppliers while ensuring continuity in drug availability.

Victoria Korotenko, Head of Foreign Registration at the Autonomous Non-Commercial Organization “National Scientific Centre for Pharmacovigilance,” stated, “We help our international colleagues prepare their drug registration dossiers in the required format and provide support throughout the entire process. We also assist foreign companies in preparing drug safety reports.”

She further clarified that clinical trial data generated in India can be accepted during the registration process if it meets international standards. However, additional studies may be required in certain cases, particularly for generics and biosimilars.

Indian companies are also expected to comply with pharmacovigilance norms, including reporting adverse drug reactions.

Institutional support is being reinforced through platforms such as the Business Council for Cooperation with India, which facilitates engagement between companies, industry bodies, and government agencies.

Stay tuned for more such updates on Digital Health News